WCLC 2025 - Posters & ePosters-EP.07.25 Real-World Treatment Patterns and Outcomes of Stage I-III Resectable Non-Small Cell Lung Cancer (NSCLC) in Portugal

EP.07.25 Real-World Treatment Patterns and Outcomes of Stage I-III Resectable Non-Small Cell Lung Cancer (NSCLC) in Portugal

Back to course

Pdf Summary

This multicenter, retrospective observational study in Portugal analyzed real-world treatment patterns and outcomes among 401 patients diagnosed with potentially resectable stage I-III non-small cell lung cancer (NSCLC) between July 2016 and December 2017, with follow-up until June 2022. The study aimed to describe patient characteristics, treatment modalities, and overall survival (OS) by disease stage.<br /><br />Key findings show that 59% of patients were stage I, 21% stage II, and 20% stage III at diagnosis. Most patients had adenocarcinoma histology (80%) and a smoking history, with 30% current smokers. Genomic testing was conducted in 166 patients, revealing common mutations in EGFR (30%), KRAS (11%), and ALK (8%). PD-L1 testing showed that 56% expressed less than 1% positive cells.<br /><br />Treatment varied by stage. For stage I, surgery alone was the predominant treatment (67%), while stages II (71%) and III (46%) commonly received surgery followed by adjuvant therapy (AT). Neoadjuvant therapy (NAT) was most frequent in stage III patients. Among non-surgical patients, most stage I and II patients received radiotherapy (RT) only, whereas stage III patients frequently received combined RT and systemic therapy. Stereotactic Body Radiation Therapy (SBRT) was the most common RT modality among non-surgical patients. Carboplatin plus vinorelbine was the most often used chemotherapy regimen in both NAT and AT.<br /><br />Time from diagnosis to treatment initiation was significantly longer for stage I and II patients compared to stage III. Median overall survival was 73 months for stage I and 68 months for stage II, a statistically significant difference. Median OS for stage III patients was not reached due to ongoing survival.<br /><br />The study highlights stage-dependent differences in NSCLC management and survival in Portugal. It underscores the importance of surgery alone for early-stage disease, multimodal treatment for advanced stages, and timely treatment initiation. The authors advocate ongoing real-world data evaluation to refine therapeutic strategies, particularly with emerging immune checkpoint inhibitors, to improve outcomes in resectable and unresectable NSCLC.

Asset Subtitle

Marta Soares

Meta Tag

Speaker Marta Soares

Topic Early-Stage Non-small Cell Lung Cancer

Keywords

non-small cell lung cancer

NSCLC

stage I-III

Portugal

adenocarcinoma

EGFR mutation

KRAS mutation

ALK mutation

surgery

overall survival